Apis Flora

Apis Flora is a Brazilian biotechnology and pharmaceutical company specializing in the development of bee-derived products, particularly standardized propolis extracts. Founded in 1982, the company is a global leader in propolis research, having developed the EPP-AF (Extract of Propolis-Apis Flora) platform, which ensures chemical and biological standardization of its extracts. Their portfolio includes a wide range of health products, including wound healing gels, oral sprays, and dietary supplements, many of which are backed by clinical trials. Apis Flora operates a state-of-the-art manufacturing facility in Ribeirão Preto and collaborates extensively with academic institutions to explore the therapeutic potential of honeybee products. The company's research focus includes immunology, infectious diseases, and dermatology, with a notable Phase 3 trial investigating propolis as an adjunct treatment for COVID-19.